Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson's disease

Nature Medicine

Volumn 24, Issue 7, 2018, Pages 931-938

  Yun, Seung Pil ^a,b   Kam, Tae In ^a   Panicker, Nikhil ^a   Kim, Sangmin ^a   Oh, Yumin ^a,c   Park, Jong Sung ^a,c   Kwon, Seung Hwan ^a   Park, Yong Joo ^a,c   Karuppagounder, Senthilkumar S ^a,b   Park, Hyejin ^a   Kim, Sangjune ^a   Oh, Nayeon ^a   Kim, Nayoung Alice ^a   Lee, Saebom ^a   Brahmachari, Saurav ^a,b   Mao, Xiaobo ^a,b   Lee, Jun Hee ^d   Kumar, Manoj ^a   An, Daniel ^a   Kang, Sung Ung ^a   Lee, Yunjong ^e   Lee, Kang Choon ^f   Na, Dong Hee ^g   Kim, Donghoon ^a   Lee, Sang Hun ^h   Roschke, Viktor V ⁱ   Liddelow, Shane A ^j   Mari, Zoltan ^a   Barres, Ben A ^j   Dawson, Valina L ^a,b   Lee, Seulki ^a,c   Dawson, Ted M ^a,b,k   Ko, Han Seok ^a,b,k   more..

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ADRIENNE HELIS MALVIN MEDICAL RESEARCH FOUNDATION   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^e Sungkyunkwan University School of Medicine   (South Korea)

^f Sungkyunkwan University   (South Korea)

^g Chung Ang University   (South Korea)

^h Soonchunhyang University   (South Korea)

ⁱ Neuraly Inc   (United States)

^j STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k Diana Helis Henry Medical Research Foundation   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; NEUROPROTECTIVE AGENT; NLY 01; UNCLASSIFIED DRUG; AMYLOID;

A1 REACTIVE ASTROCYTE; ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASTROCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DRUG MECHANISM; FEMALE; FIBRIL; HUMAN; MALE; MICROGLIA; MIDDLE AGED; MOUSE; NERVE DEGENERATION; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PHENOTYPE; PRIORITY JOURNAL; VERY ELDERLY; ANIMAL; C57BL MOUSE; DISEASE MODEL; METABOLISM; PATHOLOGY; TRANSGENIC MOUSE;

ALPHA-SYNUCLEIN; AMYLOID; ANIMALS; ASTROCYTES; DISEASE MODELS, ANIMAL; HUMANS; MICE, INBRED C57BL; MICE, TRANSGENIC; MICROGLIA; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE;

EID: 85048318201     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/s41591-018-0051-5     Document Type: Article

References (44)

1. Liddelow, S. A. &Barres, B. A. Reactive astrocytes: production, function, and therapeutic potential. Immunity 46, 957-967 (2017).
2. Liddelow, S. A. et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature 541, 481-487 (2017).
3. Athauda, D. &Foltynie, T. The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of action. Drug Discov. Today 21, 802-818 (2016).
4. Aviles-Olmos, I. et al. Exenatide and the treatment of patients with Parkinson's disease. J. Clin. Invest. 123, 2730-2736 (2013).
5. Chen, S. et al. Glucagon-like peptide-1 protects hippocampal neurons against advanced glycation end product-induced tau hyperphosphorylation. Neuroscience 256, 137-146 (2014).
6. Harkavyi, A. &Whitton, P. S. Glucagon-like peptide 1 receptor stimulation as a means of neuroprotection. Br. J. Pharmacol. 159, 495-501 (2010).
7. Li, Y. et al. Liraglutide is neurotrophic and neuroprotective in neuronal cultures and mitigates mild traumatic brain injury in mice. J. Neurochem. 135, 1203-1217 (2015).
8. Li, Y. et al. GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proc. Natl Acad. Sci. USA 106, 1285-1290 (2009).
9. Meier, J. J. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat. Rev. Endocrinol. 8, 728-742 (2012).
10. Rachmany, L. et al. Exendin-4 induced glucagon-like peptide-1 receptor activation reverses behavioral impairments of mild traumatic brain injury in mice. Age (Dordr.) 35, 1621-1636 (2013).
11. Teramoto, S. et al. Exendin-4, a glucagon-like peptide-1 receptor agonist, provides neuroprotection in mice transient focal cerebral ischemia. J. Cereb. Blood Flow Metab. 31, 1696-1705 (2011).
12. Tweedie, D. et al. Blast traumatic brain injury-induced cognitive deficits are attenuated by preinjury or postinjury treatment with the glucagon-like peptide-1 receptor agonist, exendin-4. Alzheimers Dement. 12, 34-48 (2016).
13. Athauda, D. et al. Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet 390, 1664-1675 (2017).
14. Luk, K. C. et al. Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 338, 949-953 (2012).
15. Mao, X. et al. Pathological α-synuclein transmission initiated by binding lymphocyte-activation gene 3. Science 353, aah3374 (2016).
16. Lee, M. K. et al. Human α-synuclein-harboring familial Parkinson's disease-linked Ala-53 - Thr mutation causes neurodegenerative disease with α-synuclein aggregation in transgenic mice. Proc. Natl Acad. Sci. USA 99, 8968-8973 (2002).
17. Cabezas, R. et al. Astrocytic modulation of blood brain barrier: perspectives on Parkinson's disease. Front. Cell. Neurosci. 8, 211 (2014).
18. Gray, M. T. &Woulfe, J. M. Striatal blood-brain barrier permeability in Parkinson's disease. J. Cereb. Blood Flow Metab. 35, 747-750 (2015).
19. Polinski, N. K. et al. Best practices for generating and using alpha-synuclein pre-formed fibrils to model parkinson's disease in rodents. J. Parkinsons Dis. https://doi.org/10.3233/JPD-171248 (2018).
20. Brahmachari, S. et al. Activation of tyrosine kinase c-Abl contributes to α-synuclein-induced neurodegeneration. J. Clin. Invest. 126, 2970-2988 (2016).
21. Zhang, Y. et al. An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. J. Neurosci. 34, 11929-11947 (2014).
22. Kim, C., Lee, H. J., Masliah, E. &Lee, S. J. Non-cell-autonomous neurotoxicity of α-synuclein through microglial Toll-like receptor 2. Exp. Neurobiol. 25, 113-119 (2016).
23. Daher, J. P. et al. Neurodegenerative phenotypes in an A53T α-synuclein transgenic mouse model are independent of LRRK2. Hum. Mol. Genet. 21, 2420-2431 (2012).
24. Harms, A. S. et al. Peripheral monocyte entry is required for alpha-synuclein induced inflammation and neurodegeneration in a model of Parkinson disease. Exp. Neurol. 300, 179-187 (2018).
25. Martinez, F. O. &Gordon, S. The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000Prime Rep. 6, 13 (2014).
26. Allen Reish, H. E. &Standaert, D. G. Role of α-synuclein in inducing innate and adaptive immunity in Parkinson disease. J. Parkinsons Dis. 5, 1-19 (2015).
27. Goncalves, A. et al. Protective effect of a GLP-1 analog on ischemia-reperfusion induced blood-retinal barrier breakdown and inflammation. Invest. Ophthalmol. Vis. Sci. 57, 2584-2592 (2016).
28. Gullo, F. et al. Plant polyphenols and exendin-4 prevent hyperactivity and TNF-α release in LPS-treated in vitro neuron/astrocyte/microglial networks. Front. Neurosci. 11, 500 (2017).
29. Kim, S., Moon, M. &Park, S. Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease. J. Endocrinol. 202, 431-439 (2009).
30. Lee, C.-H. et al. Activation of glucagon-like peptide-1 receptor promotes neuroprotection in experimental autoimmune encephalomyelitis by reducing neuroinflammatory responses. Mol. Neurobiol. 55, 3007-3020 (2018).
31. Li, Y. et al. Exendin-4 ameliorates motor neuron degeneration in cellular and animal models of amyotrophic lateral sclerosis. PLoS ONE 7, e32008 (2012).
32. Wu, H.-Y., Tang, X.-Q., Liu, H., Mao, X.-F. &Wang, Y.-X. Both classic Gs-cAMP/PKA/CREB and alternative Gs-cAMP/PKA/p38β /CREB signal pathways mediate exenatide-stimulated expression of M2 microglial markers. J. Neuroimmunol. 316, 17-22 (2018).
33. Ventorp, F. et al. Exendin-4 treatment improves LPS-induced depressive-like behavior without affecting pro-inflammatorycytokines. J. Parkinsons Dis. 7, 263-273 (2017).
34. Ji, C. et al. A novel dual GLP-1 and GIP receptor agonist is neuroprotective in the MPTP mouse model of Parkinson's disease by increasing expression of BNDF. Brain Res. 1634, 1-11 (2016).
35. Salcedo, I., Tweedie, D., Li, Y. &Greig, N. H. Neuroprotective and neurotrophic actions of glucagon-like peptide-1: an emerging opportunity to treat neurodegenerative and cerebrovascular disorders. Br. J. Pharmacol. 166, 1586-1599 (2012).
36. Volpicelli-Daley, L. A., Luk, K. C. &Lee, V. M. Addition of exogenous α-synuclein preformed fibrils to primary neuronal cultures to seed recruitment of endogenous α-synuclein to Lewy body and Lewy neurite-like aggregates. Nat. Protoc. 9, 2135-2146 (2014).
37. Kim, T. H. et al. Mono-PEGylated dimeric exendin-4 as high receptor binding and long-acting conjugates for type 2 anti-diabetes therapeutics. Bioconjug. Chem. 22, 625-632 (2011).
38. Kim, T. H. et al. Site-specific PEGylated exendin-4 modified with a high molecular weight trimeric PEG reduces steric hindrance and increases type 2 antidiabetic therapeutic effects. Bioconjug. Chem. 23, 2214-2220 (2012).
39. Karuppagounder, S. S. et al. The c-Abl inhibitor, nilotinib, protects dopaminergic neurons in a preclinical animal model of Parkinson's disease. Sci. Rep. 4, 4874 (2014).
40. Lee, Y. et al. Parthanatos mediates AIMP2-activated age-dependent dopaminergic neuronal loss. Nat. Neurosci. 16, 1392-1400 (2013).
41. Kim, S. et al. GBA1 deficiency negatively affects physiological α-synuclein tetramers and related multimers. Proc. Natl Acad. Sci. USA 115, 798-803 (2018).
42. Panicker, N. et al. Fyn kinase regulates microglial neuroinflammatory responses in cell culture and animal models of Parkinson's disease. J. Neurosci. 35, 10058-10077 (2015).
43. Andrabi, S. A. et al. Iduna protects the brain from glutamate excitotoxicity and stroke by interfering with poly(ADP-ribose) polymer-induced cell death. Nat. Med. 17, 692-699 (2011).
44. Wang, Y. et al. A nuclease that mediates cell death induced by DNA damage and poly(ADP-ribose) polymerase-1. Science 354, aad6872 (2016).